Calculating Glucagon-Like Pepide-1 Receptor Agonist-Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: reported AEs
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Strikingly, GLP-1RA users showed increased RPs as compared to the total FAERS RPs: MTC 0.071% (50.7-fold increase) and PTC 0.164% (18.9-fold increase) with significantly elevated IRRs (p = 0.0001) compared to reference groups. [CONCLUSION] GLP-1RAs showed a higher RP for MTC compared to other drug classes, warranting prospective studies to investigate further.
OpenAlex 토픽 ·
Thyroid Cancer Diagnosis and Treatment
Neuroendocrine Tumor Research Advances
Diabetes Treatment and Management
[BACKGROUND] GLP-1 receptor agonists carry an FDA boxed warning for medullary thyroid carcinoma (MTC) risk, though conflicting clinical evidence has generated tremendous controversy regarding this ass
- 표본수 (n) 109
- p-value p = 0.0001
APA
Stella J. D'Arcy, Sophia L. Kennedy, et al. (2026). Calculating Glucagon-Like Pepide-1 Receptor Agonist-Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System.. Head & neck. https://doi.org/10.1002/hed.70286
MLA
Stella J. D'Arcy, et al.. "Calculating Glucagon-Like Pepide-1 Receptor Agonist-Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System.." Head & neck, 2026.
PMID
42003032 ↗
Abstract 한글 요약
[BACKGROUND] GLP-1 receptor agonists carry an FDA boxed warning for medullary thyroid carcinoma (MTC) risk, though conflicting clinical evidence has generated tremendous controversy regarding this association.
[METHODS] We analyzed SEER and FAERS databases to compare MTC and papillary thyroid cancer (PTC) reporting proportions (RP) between the general population and GLP-1RA users (n = 109 168), controlling for surveillance bias by comparing against other endocrine and non-endocrine drugs. Negative binomial regression was used to estimate the incidence rate ratios (IRR) in the FAERS dataset among patients with reported AEs.
[RESULTS] The 10-year mean MTC RP in SEER/FAERS was 0.0002%/0.0014%, while PTC was 0.012%/0.0087%. Strikingly, GLP-1RA users showed increased RPs as compared to the total FAERS RPs: MTC 0.071% (50.7-fold increase) and PTC 0.164% (18.9-fold increase) with significantly elevated IRRs (p = 0.0001) compared to reference groups.
[CONCLUSION] GLP-1RAs showed a higher RP for MTC compared to other drug classes, warranting prospective studies to investigate further.
[METHODS] We analyzed SEER and FAERS databases to compare MTC and papillary thyroid cancer (PTC) reporting proportions (RP) between the general population and GLP-1RA users (n = 109 168), controlling for surveillance bias by comparing against other endocrine and non-endocrine drugs. Negative binomial regression was used to estimate the incidence rate ratios (IRR) in the FAERS dataset among patients with reported AEs.
[RESULTS] The 10-year mean MTC RP in SEER/FAERS was 0.0002%/0.0014%, while PTC was 0.012%/0.0087%. Strikingly, GLP-1RA users showed increased RPs as compared to the total FAERS RPs: MTC 0.071% (50.7-fold increase) and PTC 0.164% (18.9-fold increase) with significantly elevated IRRs (p = 0.0001) compared to reference groups.
[CONCLUSION] GLP-1RAs showed a higher RP for MTC compared to other drug classes, warranting prospective studies to investigate further.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Temporal trends in second primary malignancies among long-term survivors of multiple myeloma across treatment eras: a population-based analysis of the SEER database.
- Survival outcomes and treatment patterns in primary vertebral diffuse large B-cell lymphoma.
- Clinicopathological features and survival outcomes of patients with different distant and lymph node metastasis in pancreatic cancer.
- Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.
- Survival Trends and Prognostic Modeling in ALK-Positive Anaplastic Large Cell Lymphoma: A Population-Based Study in the Brentuximab Vedotin Era.
- Development of machine learning and nomogram models to predict lung metastasis and prognosticate survival in breast cancer.